



Sensome, formerly Instent, raises €4.7m to bring the world's first connected stroke guidewire to patients

Sensome's first application of its AI-powered micro-sensor technology can detect the composition of the blockage in the brain during stroke treatment

PARIS, France - July 10TH, 2017 – Sensome, formerly Instent, a company developing a revolutionary micro-sensor technology for smart medical devices out of France's Ecole polytechnique, announced today that it has completed its €4.7m seed round to bring its first product to clinical trials. Venture capital firm Kurma Diagnostics led a syndicate with the new Paris-Saclay Seed Fund and Idinvest, joined by a group of business angels.

Sensome's novel sensing technology can be integrated with any medical device to reliably identify biological tissues in contact with the device. The technology combines micrometric impedance sensors that communicate wirelessly outside the body and machine learning algorithms for accurate and predictive real-time analysis.

Sensome's first product integrates its proprietary technology with a guidewire for the treatment of ischemic stroke. When a brain blood vessel is blocked by a clot, millions of brain cells die every minute. Depending on the composition of the blood clot, the choice of tool to remove the clot significantly impacts the time to reopen the artery, ranging from minutes to hours. Sensome's connected stroke guidewire will help select the fastest device to reopen the vessel for each patient. Ischemic stroke affects over 1.5 million people across Europe and the US every year.

"This seed round allows us to prepare first-in-human testing of our neurovascular product next year and to enter the stroke space", says Franz Bozsak, CEO of Sensome, who co-founded the company with Abdul Barakat, professor at the Hydrodynamics Laboratory at Ecole polytechnique. "The connected stroke guidewire will finally provide physicians with the information they need to reduce procedure times. This first smart product with Sensome inside will pave the way for future devices integrating our technology for the benefit of patients."

About Sensome

Sensome was founded in 2014 as a spin-off from Ecole polytechnique. It developed a revolutionary micro-sensor technology that turns invasive medical devices into connected healthcare devices. Sensome's patented sensor technology allows identification of biological tissues upon contact. The first application is a connected guidewire for the treatment of ischemic stroke.

www.sensome.com

About Kurma Partners

Created in 2009, Kurma Partners is a European leading venture capital group specialized in Life Sciences and managing Kurma Biofund I, Kurma biofund II and its accelerator fund, Kurma Diagnostics. The company has more than 250M€ under management and develops an investment strategy supported by both the selection of best investment opportunity in Europe and

the development of a “proprietary” portfolio of company in which Kurma intervenes at creation stage.

www.kurmapartners.com

About Paris-Saclay Seed Fund

Paris-Saclay Seed Fund was launched in 2016 as a unique initiative to support the most promising startups emerging from the leading research & innovation cluster Université Paris-Saclay. The Fund is managed by two renowned venture capital firms : Partech Ventures, a global investment firm specializing in digital and new technologies, and Kurma Partners, a leading venture capital group in Life Sciences. This 50M€ fund will invest in Seed and Series A startups.

www.seedfund.parissaclay.com

About Idinvest Partners

With almost €8 billion under management, Idinvest Partners is a leading pan-European private equity firm focused on the mid-market segment. Idinvest Partners has developed several complementary areas of expertise including: investments in innovative European start-ups; mid-market direct lending (unitranche, senior loans and junior financing); primary and secondary investments in unlisted European companies, and private equity consulting. Founded under the name AGF Private Equity in 1997, Idinvest Partners was formerly part of Allianz until 2010 when it became an independent firm.

www.idinvest.com

For more information please contact: Franz Bozsak, press@sensome.com or call +33 1 69 33 52 66